Overview

CPX-351 in Higher Risk Myelodysplastic Syndromes

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

Study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies